{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".827","upperLimit":".994","value":".949"},{"groupId":"OG001","lowerLimit":".786","upperLimit":".983","value":".921"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Proportion of patients that went two of more cycles of treatment without discontinuing treatment for progression or intolerability.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Phase II Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"42 days","title":"Disease Control Rate (DCR), Defined as Stable Disease (SD) and Better According to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)","type":"SECONDARY","unitOfMeasure":"proportion of partcipants"}